Serum S100B Protein Levels in Patients with Panic Disorder: Effect of Treatment with Selective Serotonine Reuptake Inhibitors

Objective Altered serum S100B protein levels have been shown in several psychiatric disorders. Our aim was to investigate whether plasma S100B is different in patients with panic disorder (PD) when compared with controls. Our second aim was to investigate whether treatment with SSRIs have an effect on S100B levels in patients with PD. Methods The sample included 32 patients diagnosed with PD (21 women, 11 men) per DSM-IV criteria and 21 healthy controls (11 women, 10 men). S100B levels were measured with BioVendor Human S100B ELISA (Enzyme Linked Immunosorbent Assay) kit. Results 14 patients were not on drug treatment (43.8%) while 18 patients were taking various SSRls. Median S100B value was 151.7 pg/mL (minimum-maximum: 120.4-164.7 pg/mL) in the control group, 147.4 pg/mL (minimum-maximum: 138.8-154.1 pg/mL) in the drug free group and 153.0 pg/mL (minimum-maximum: 137.9-164.7 pg/mL) in the treatment group. Kruskal-Wallis analysis showed a significant diffrerence among the three groups (z=9.9, df=2, p=0.007). Follow up Mann-Whitney-U tests indicated that while the control and the patients with treatment were not significantly different (z=-0.05, p=0.96), there were significant differences between the control group and untreated patients (z=-2.6, p=0.009) and treated and untreated patients (z=-3.0, p=0.003). Conclusion Our results suggested that, serum S100B protein level might be decreased in untreated PD patients and that patients who were treated with SSRIs had similar S100B level to healthy controls.

Yazar Kaya, Berna Cagatay
Karadag, Hasan
Oner, Ozgur
Kart, Aysegul
Turkcapar, Mehmet Hakan
Yayın Türü Article
Tek Biçim Adres https://hdl.handle.net/20.500.12628/3314
Tek Biçim Adres 10.4306/pi.2015.12.2.260
Konu Başlıkları S100B protein
Panic disorder
Selective serotonine reuptake inhibitors
Koleksiyonlar Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed | SOBİAD
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu
Dergi Adı PSYCHIATRY INVESTIGATION
Dergi Cilt Bilgisi 12
Dergi Sayısı 2
Sayfalar 260 - 262
Yayın Yılı 2015
Eser Adı
[dc.title]
Serum S100B Protein Levels in Patients with Panic Disorder: Effect of Treatment with Selective Serotonine Reuptake Inhibitors
Yazar
[dc.contributor.author]
Kaya, Berna Cagatay
Yazar
[dc.contributor.author]
Karadag, Hasan
Yazar
[dc.contributor.author]
Oner, Ozgur
Yazar
[dc.contributor.author]
Kart, Aysegul
Yazar
[dc.contributor.author]
Turkcapar, Mehmet Hakan
Yayın Yılı
[dc.date.issued]
2015
Yayıncı
[dc.publisher]
KOREAN NEUROPSYCHIATRIC ASSOC
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Objective Altered serum S100B protein levels have been shown in several psychiatric disorders. Our aim was to investigate whether plasma S100B is different in patients with panic disorder (PD) when compared with controls. Our second aim was to investigate whether treatment with SSRIs have an effect on S100B levels in patients with PD. Methods The sample included 32 patients diagnosed with PD (21 women, 11 men) per DSM-IV criteria and 21 healthy controls (11 women, 10 men). S100B levels were measured with BioVendor Human S100B ELISA (Enzyme Linked Immunosorbent Assay) kit. Results 14 patients were not on drug treatment (43.8%) while 18 patients were taking various SSRls. Median S100B value was 151.7 pg/mL (minimum-maximum: 120.4-164.7 pg/mL) in the control group, 147.4 pg/mL (minimum-maximum: 138.8-154.1 pg/mL) in the drug free group and 153.0 pg/mL (minimum-maximum: 137.9-164.7 pg/mL) in the treatment group. Kruskal-Wallis analysis showed a significant diffrerence among the three groups (z=9.9, df=2, p=0.007). Follow up Mann-Whitney-U tests indicated that while the control and the patients with treatment were not significantly different (z=-0.05, p=0.96), there were significant differences between the control group and untreated patients (z=-2.6, p=0.009) and treated and untreated patients (z=-3.0, p=0.003). Conclusion Our results suggested that, serum S100B protein level might be decreased in untreated PD patients and that patients who were treated with SSRIs had similar S100B level to healthy controls.
Açıklama
[dc.description]
WOS: 000353367600015
Açıklama
[dc.description]
PubMed: 25866528
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Konu Başlıkları
[dc.subject]
S100B protein
Konu Başlıkları
[dc.subject]
Panic disorder
Konu Başlıkları
[dc.subject]
Selective serotonine reuptake inhibitors
Haklar
[dc.rights]
info:eu-repo/semantics/openAccess
ISSN
[dc.identifier.issn]
1738-3684
ISSN
[dc.identifier.issn]
1976-3026
İlk Sayfa Sayısı
[dc.identifier.startpage]
260
Son Sayfa Sayısı
[dc.identifier.endpage]
262
Dergi Adı
[dc.relation.journal]
PSYCHIATRY INVESTIGATION
Dergi Sayısı
[dc.identifier.issue]
2
Dergi Cilt Bilgisi
[dc.identifier.volume]
12
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.4306/pi.2015.12.2.260
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/3314
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
9
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
16 Ocak 2024 11:46
Google Kontrol
Tıklayınız
patients treatment controls untreated (minimum-maximum pg/mL) levels control significant healthy treated protein whether investigate different Kruskal-Wallis diffrerence showed analysis decreased similar groups between differences Conclusion results significantly suggested indicated Mann-Whitney-U Follow Objective second diagnosed included
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms